The Global Hemophilia Treatment Market is valued at USD 11.07 Billion in 2021 and is expected to reach USD 16.44 Billion by 2028 with a CAGR of 5.8% over the forecast period.
Increasing prevalence of hemophilia, rising advancements in the healthcare industry, and growing government initiatives to promote awareness about hemophilia treatment are some of the major factors driving the growth of the Global Hemophilia Treatment Market.
Download Free Exclusive Sample (200 Pages PDF) Report @:
Scope of Global Hemophilia Treatment Market Report-
Hemophilia is a rare disorder in which the patient’s blood does not clot normally because it does not have enough blood-clotting proteins (clotting factors). If patients have hemophilia, they may bleed longer after an injury than if the patient had normal blood clots. Several types of clotting factors are associated with different types of hemophilia. The main treatment for severe hemophilia is to replace the specific clotting factor patients need through a tube placed in a vein. Hemophilia treatment involves administering drugs intravenously or intranasally to prevent frequent internal bleeding that can lead to arthritis or joint destruction or infection. It is an inherited bleeding disorder that can cause persistent bleeding or discharge after injury or surgery. In severe cases, prolonged bleeding occurs after minor trauma or even in the absence of injury.
Key Players of Global Hemophilia Treatment Market Report:
Some major key players for the global hemophilia treatment market report cover prominent players like Grifols SA, CSL Ltd., Octapharma AG, Novo Nordisk, Kedrion, Pfizer, Inc., Bayer AG, Biogen Idec, Inc., Hospira, Inc., Baxter International, Inc., and others.
Global Hemophilia Treatment Market Segmentation:
By Disease Type:
- Von Willebrand Disease
- Hemophilia A
- Hemophilia B
By Product Type:
- Plasma-derived Factor Concentrate
- Recombinant Factor Concentrate
By Route of Administration:
- Nasal Spray
- Replacement Therapy
- Immune Tolerance Induction Therapy
- Gene Therapy
- Hospital Pharmacy
- Retail Pharmacy
Get Methodology of the Hemophilia Treatment Market Report @:
Global Hemophilia Treatment Market Recent Developments-
The European Commission (EC) Granted Approval for BioMarin’s Gene Therapy to Treat Hemophilia A
On August 25th, 2022- the European Commission (EC) granted a conditional marketing authorization (CMA) for BioMarin Pharmaceutical’s gene therapy, Roctavian (valoctocogene roxaparvovec), to treat adults with severe hemophilia A (congenital factor VIII deficiency). Treatment is indicated for patients with no history of factor VIII inhibitors and no detectable antibodies to adeno-associated virus serotype 5 (AAV5).
Takeda Launched Adynovate for Prophylaxis Treatment of Hemophiliac Patients in India.
On May 17th, 2022- Takeda Pharmaceutical Company Limited launched an extended half-life recombinant factor VIII (rFVIII) treatment under the brand name Adynovate using an established technology (controlled PEGylation) for hemophilia A patients. Takeda is a global, values-based, R&D-driven biopharmaceutical leader with an innovative rare disease portfolio in India.
FDA Approved Additional Treatment for Adults and Adolescents with Hemophilia A or B and Inhibitors
On April 1st, 2020- the US Food and Drug Administration approved Sevenfact [coagulation factor VIIa (recombinant)-jncw] for the treatment and control of bleeding episodes in adults and adolescents 12 years of age or older with hemophilia A or B inhibitors (neutralizing antibodies). Seven facts contain an active ingredient expressed in genetically engineered rabbits.
North America Holds a Major Share in the Global Hemophilia Treatment Market:
Geographically, North America is holding a major share in the global hemophilia treatment market within the forecast period due to the increasing number of hemophilic patients, rising demand for prophylactic treatments, and growing medical research these factors boost the market. An increasing number of hemophilic patients is driving the growth of the hemophilia treatment market. According to the U.S. Centers for Disease Control, about 3 million people nationwide suffer from bleeding disorders. And also, according to ASH Clinical, on February 1st, 2020; Approximately 20,000 people in the US are living with the genetic bleeding disorder hemophilia, and more than 60% of those people have moderate or severe hemophilia that requires lifelong treatment with expensive medications and clotting factors. In addition, the rising demand for prophylactic treatments is another factor supplementing the market growth in this region. For instance, as per the news published, on January 31st, 2022; FDA approved prophylactic treatment with VONVENDI for adult patients living with severe type 3 von Willebrand disease (VWD). Due to the growing market benefits of all these factors, North America holds a major share in the global hemophilia treatment market.
The Asia Pacific is the fastest-growing region in the global hemophilia treatment market due to increasing investments in research and development of new products for the treatment of hemophilia, the rising number of hemophilic patients, and technological advancements these factors boost the market. For instance, Hemophilia, a rare disease, has been a long-standing problem with a small but critical number of cases. In the Indian context, more than 1,36,000 people have been diagnosed (according to prevalence). The number is 1 in every 10,000 male births. Of the total number, 19,690 have been reported as Hem-A patients. At a time when the diagnosis rate of hemophilia is as low as 13 percent, spreading awareness about it has become imperative. And the government of India is currently working on it on a large scale. which will provide huge opportunities for the market in India as well in the coming time. In other countries in Asia Pacific, such government campaigns are also underway, which can greatly expand the market in Asia Pacific in the coming period.
By Regional Analysis:
- Rest of Europe
- South Korea
- Rest Of APAC
- Rest of South America
Middle East and Africa
- Saudi Arabia
- South Africa
- Rest Of MEA
Buy Now @
This comprehensive report will provide:
- Enhance your strategic decision making
- Assist with your research, presentations, and business plans
- Show which emerging market opportunities to focus on
- Increase your industry knowledge
- Keep you up-to-date with crucial market developments
- Allow you to develop informed growth strategies
- Build your technical insight
- Illustrate trends to exploit
- Strengthen your analysis of competitors
- Provide risk analysis, helping you avoid the pitfalls other companies could make
- Ultimately, help you to maximize profitability for your company.
Our Market Research Solution Provides You Answer to Below Mentioned Question:
- Which are the driving factors responsible for the growth of the market?
- Which are the roadblock factors of this market?
- What are the new opportunities, by which market will grow in coming years?
- What are the trends of this market?
- Which are the main factors responsible for new product launches?
- How big are the global & regional markets in terms of revenue, sales, and production?
- How far will the market grow in the forecast period in terms of revenue, sales, and production?
- Which region is dominating the global market and what are the market shares of each region in the overall market in 2022?
- How will each segment grow over the forecast period and how much revenue will these segments account for in 2028?
- Which region has more opportunities?
Key Benefits of Global Hemophilia Treatment Market Report:
- Global Hemophilia Treatment Market report covers in-depth historical and forecast analysis
- Global Hemophilia Treatment Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level.
- Global Hemophilia Treatment Market report helps to identify opportunities in marketplace.
- Global Hemophilia Treatment Market report covers extensive analysis of emerging trends and competitive landscape.
Get Access to the Full Report Here:
The Global Surgical Instrument Tracking Systems Market in terms of revenue was worth of USD 193.8 Million in 2021 and is Projected to reach USD 513.1 Million by 2028, growing at a CAGR of 14.92% from 2021 to 2027.
Animal Vaccine Market was worth of USD 11.13 billion in 2021 and it is expected to reach 20.48 billion by the end of 2028 with the CAGR of 9.1% during Forecast Period.
Hemophilia Gene Therapy Market is valued at USD 331.4 Million in 2021 and expected to reach USD 4092.6 Million by 2028 with a CAGR of 43.2% over the forecast period.
Global Bioinformatics Market in terms of revenue was worth of USD 10.82 Billion in 2021 and expected to reach USD 24.07 Billion by 2028, growing at a CAGR of 12.1% from 2021 to 2028.
Colorectal Cancer Market is valued at USD 11.83 Billion in 2021 and is expected to reach USD 16.21 Billion by 2028 with a CAGR of 5.40% over the forecast period.
Global Medical Tricorder Market is valued at USD 3425.4 Million in 2021 and is expected to reach USD 5411.2 Million by 2028 with a CAGR of 6.75% over the forecast period.
Global Healthcare CRM Market is valued at USD 12.53 Billion in 2021 and is expected to reach USD 31.54 Billion by 2028 with a CAGR of 14.1% over the forecast period.
The Global Metaverse in Healthcare Market is valued at USD 5056.4 Million in 2021 and is expected to reach USD 7453.6 Million by 2028 with a CAGR of 33.7% over the forecast period.
Global Demand For Advanced Wound Care Market, in terms of revenue, was estimated to be USD 9.01 billion in 2018 and is expected to reach USD 13.27 billion in 2025, growing at a CAGR of 5.85% from 2019 to 2025.
According to Brandessence Market Research latest research study says Global demand for biophotonics market size in terms of revenue, was worth of USD 53.28 Billion in 2020. The biophotonics market is likely to reach USD 109.23 Billion by 2027 end, growing at a robust 10.8% CAGR.
The Global Sterility Testing Market in terms of revenue was worth of USD 1036.13 Million in 2021 and expected to reach USD 2193.8 Million by 2028, growing at a CAGR of 12.6% from 2021 to 2028.
i-Factor: Live Market intelligence platform
I-Factor is our guaranteed seal to keep our clients ahead of the competition, always. This knowledge platform delivers real-time updates on key economic indicators, competitive landscape, changing demand, trends, customized regional insights, and more. The platform visualizes key data points to help make decision making agile, trustworthy, and holistic. Register for free trial here at https://brandessenceresearch.com/i-factor/login/userRegister
Brandessence Market Research & Consulting Pvt ltd.
Brandessence Market Research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.